285 related articles for article (PubMed ID: 32112101)
1. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence.
Losa M; Castellino L; Pagnano A; Rossini A; Mortini P; Lanzi R
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32112101
[TBL] [Abstract][Full Text] [Related]
2. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
J Clin Endocrinol Metab; 2015 Aug; 100(8):3132-9. PubMed ID: 26057181
[TBL] [Abstract][Full Text] [Related]
3. Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study.
Smith TR; Cote DJ; Jane JA; Laws ER
J Neurosurg Pediatr; 2016 Oct; 18(4):408-412. PubMed ID: 27286443
[TBL] [Abstract][Full Text] [Related]
4. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).
Verhelst J; Kendall-Taylor P; Erfurth EM; Price DA; Geffner M; Koltowska-Häggström M; Jönsson PJ; Wilton P; Abs R
J Clin Endocrinol Metab; 2005 Aug; 90(8):4636-43. PubMed ID: 15928246
[TBL] [Abstract][Full Text] [Related]
5. Replacement therapy with growth hormone and pituitary tumor recurrence: the relevance of the problem.
Losa M; Gatti E; Rossini A; Lanzi R
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):75-8. PubMed ID: 19020392
[TBL] [Abstract][Full Text] [Related]
6. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?
Nguyen Quoc A; Beccaria K; González Briceño L; Pinto G; Samara-Boustani D; Stoupa A; Beltrand J; Besançon A; Thalassinos C; Puget S; Blauwblomme T; Alapetite C; Bolle S; Doz F; Grill J; Dufour C; Bourdeaut F; Abbou S; Guerrini-Rousseau L; Leruste A; Brabant S; Cavadias I; Viaud M; Boddaert N; Polak M; Kariyawasam D
J Clin Endocrinol Metab; 2023 Jul; 108(8):1929-1936. PubMed ID: 36794424
[TBL] [Abstract][Full Text] [Related]
7. New Neoplasm During GH Replacement in Adults With Pituitary Deficiency Following Malignancy: A KIMS Analysis.
Krzyzanowska-Mittermayer K; Mattsson AF; Maiter D; Feldt-Rasmussen U; Camacho-Hübner C; Luger A; Abs R
J Clin Endocrinol Metab; 2018 Feb; 103(2):523-531. PubMed ID: 29228199
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study.
Verweij T; Slagboom TNA; van Varsseveld NC; van der Lely AJ; Drent ML; van Bunderen CC
Eur J Endocrinol; 2021 Oct; 185(6):793-801. PubMed ID: 34605771
[TBL] [Abstract][Full Text] [Related]
9. Analysis of short- and long-term metabolic effects of growth hormone replacement therapy in adult patients with craniopharyngioma and non-functioning pituitary adenoma.
Profka E; Giavoli C; Bergamaschi S; Ferrante E; Malchiodi E; Sala E; Verrua E; Rodari G; Filopanti M; Beck-Peccoz P; Spada A
J Endocrinol Invest; 2015 Apr; 38(4):413-20. PubMed ID: 25330765
[TBL] [Abstract][Full Text] [Related]
10. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
[TBL] [Abstract][Full Text] [Related]
11. The effect of growth hormone on pituitary tumour growth.
Herring R; Russell-Jones D
Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):365-8. PubMed ID: 20498595
[TBL] [Abstract][Full Text] [Related]
12. Hypopituitarism after Gamma Knife surgery for postoperative nonfunctioning pituitary adenoma.
Oh JW; Sung KS; Moon JH; Kim EH; Chang WS; Jung HH; Chang JW; Park YG; Kim SH; Chang JH
J Neurosurg; 2018 Dec; 129(Suppl1):47-54. PubMed ID: 30544293
[TBL] [Abstract][Full Text] [Related]
13. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy.
Olsson DS; Buchfelder M; Schlaffer S; Bengtsson BA; Jakobsson KE; Johannsson G; Nilsson AG
Eur J Endocrinol; 2009 Nov; 161(5):663-9. PubMed ID: 19734242
[TBL] [Abstract][Full Text] [Related]
14. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile.
Batista RL; Trarbach EB; Marques MD; Cescato VA; da Silva GO; Herkenhoff CGB; Cunha-Neto MB; Musolino NR
World Neurosurg; 2018 Dec; 120():e241-e246. PubMed ID: 30138730
[TBL] [Abstract][Full Text] [Related]
15. Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy.
Gasco V; Caputo M; Cambria V; Beccuti G; Caprino MP; Ghigo E; Maccario M; Grottoli S
Endocrine; 2019 Feb; 63(2):341-347. PubMed ID: 30341707
[TBL] [Abstract][Full Text] [Related]
16. Management of Childhood-onset Craniopharyngioma in Italy: A Multicenter, 7-Year Follow-up Study of 145 Patients.
Zucchini S; Di Iorgi N; Pozzobon G; Pedicelli S; Parpagnoli M; Driul D; Matarazzo P; Baronio F; Crocco M; Iudica G; Partenope C; Nardini B; Ubertini G; Menardi R; Guzzetti C; Iughetti L; Aversa T; Di Mase R; Cassio A;
J Clin Endocrinol Metab; 2022 Feb; 107(3):e1020-e1031. PubMed ID: 34718649
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and characteristics of sellar masses in the city of Al Ain, United Arab Emirates: 2010 to 2016.
Aldahmani KM; Sreedharan J; Ismail MM; Philip J; Nair SC; Alfelasi M; Aziz W; Imran SA; Alkaabi J
Ann Saudi Med; 2020; 40(2):105-112. PubMed ID: 32241168
[TBL] [Abstract][Full Text] [Related]
18. The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke.
Jasim S; Alahdab F; Ahmed AT; Tamhane SU; Sharma A; Donegan D; Nippoldt TB; Murad MH
Endocrine; 2017 May; 56(2):267-278. PubMed ID: 27815769
[TBL] [Abstract][Full Text] [Related]
19. Rapid recurrence of craniopharyngioma following recombinant human growth hormone replacement.
Taguchi T; Takao T; Iwasaki Y; Pooh K; Okazaki M; Hashimoto K; Terada Y
J Neurooncol; 2010 Nov; 100(2):321-2. PubMed ID: 20349266
[No Abstract] [Full Text] [Related]
20. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
Child CJ; Conroy D; Zimmermann AG; Woodmansee WW; Erfurth EM; Robison LL
Eur J Endocrinol; 2015 Jun; 172(6):779-90. PubMed ID: 25810462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
